Colorectal cancer and the human gut microbiome
Ontology highlight
ABSTRACT:
PROVIDER: PRJEB12449 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| ERR1293060.fastq.gz | Fastqsanger.gz | |||
| ERR1293070.fastq.gz | Fastqsanger.gz | |||
| ERR1293080.fastq.gz | Fastqsanger.gz | |||
| ERR1293090.fastq.gz | Fastqsanger.gz | |||
| ERR1293100.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 1323 |
Similar Datasets
Project description:The goal of the study was to identify miRNAs differentially expressed in the invasive front of early and more advanced colorectal cancers, and to determine wheter miRNA profiles could differentiate between colorectal cancers with and without early metasttic progression. miRNA array data was used for analyses of associations beteen metastatic status and for associations to histopathological risk factors for metastatic progression.
2018-08-01 | GSE110402 | GEO
Project description:Normal kidney, liver, spleen, and Universal RNA from Stratagene were expression profiled across five centers (UCLA, Duke, TGen, Children's National Medical Center in Washington, DC, and University of Pennsylvania) using the Affymetrix, spotted Operon, Agilent, and Amersham arrays to identify differences in expression between microarray platforms as well as centers. To compare the four microarray platforms as well as the reproducibility across the centers. There will be expression differences between the five centers. The following array types were profiled at the centers: UCLA: Affymetrix, Amersham, Agilent TGen: Affymetrix (3000 scanner) Children's: Affymetrix (2500 scanner) Duke: Operon Oligo University of Penn.: Affymetrix Series_author: Consortium,,Cross Platform Keywords: other
2004-11-24 | GSE2004 | GEO
Project description:<p>Colorectal cancer is a heterogeneous disease arising from at least two precursors-the conventional adenoma and the serrated polyp. This dataset was used to test the relationship of the gut microbiota to specific colorectal polyp types.</p> <p>We included samples from two independent study populations based at colonoscopy clinics: the Centers for Disease Control and Prevention (CDC) Study of In-home Tests for Colorectal Cancer (SIT), and the New York University (NYU) Human Microbiome and Colorectal Tumor study. Gut microbiota were assessed in 667 colonoscopy-screened adults by 16S rRNA gene sequencing of stool samples, of which 540 were included in our analysis. Participants were categorized as conventional adenoma cases, serrated polyp cases, or polyp-free controls. CA cases were further classified as proximal or distal and as non-advanced or advanced. Serrated polyp cases were further classified as hyperplastic polyp or sessile serrated adenoma. Our results show associations between gut microbiome composition and presence of conventional adenomas, including reduced diversity and alterations in taxon abundance.</p>
| phs001381 | dbGaP
Project description:The main aim of this study is to evaluate how comparable the established colorectal primary tumor cultures are to the original tumor tissues obtained directly from patients in terms of their genomic profile for which they can be eventually utilized to improve in vitro drug assessment and facilitate personalized treatment. Here, we used colorectal cancer patient samples collected after surgery to perform a gene expression comparison study between original tissues and self-established primary cultures. Subsequently, we also investigated the possibility of using primary cells from patients’ tumors as a model for assessing drug response by characterizing the modifications in gene-drug associations of the primary cells which occurred during the establishment of cell cultures. On an auxiliary note, cytogenetic studies are only possible in cultured cells and not in tissue samples, hence, in this study we also evaluated the potential of genome stability analysis on primary cells as an alternative method to improve our understanding of the genomic changes which occur in cancer initiation and progression. Using cRNA microarrays, gene expression of low-passage colorectal tumor primary cultures were compared against colorectal tumor tissues obtained directly from patients.
2011-05-29 | E-GEOD-24993 | biostudies-arrayexpress
Project description:Normal kidney, liver, spleen, and Universal RNA from Stratagene were expression profiled across five centers (UCLA, Duke, TGen, Children's National Medical Center in Washington, DC, and University of Pennsylvania) using the Affymetrix, spotted Operon, Agilent, and Amersham arrays to identify differences in expression between microarray platforms as well as centers. To compare the four microarray platforms as well as the reproducibility across the centers. There will be expression differences between the five centers. The following array types were profiled at the centers: UCLA: Affymetrix, Amersham, Agilent TGen: Affymetrix (3000 scanner) Children's: Affymetrix (2500 scanner) Duke: Operon Oligo University of Penn.: Affymetrix Series_author: Consortium,,Cross Platform Keywords: other. This dataset is part of the TransQST collection.
2004-11-24 | E-GEOD-2004 | biostudies-arrayexpress
Project description:The clinical management of colorectal cancer patients has significantly improved due to the identification of new chemotherapeutic targets. Since rapid tumor proliferation is associated with poor patient prognosis, here we characterize the transcriptional signature of rapidly proliferating colorectal cancer cells in an attempt to identify novel candidate therapeutic targets. Therefore, the doubling time of 52 colorectal cancer cell lines was determined and genome-wide expression profiling of a subset of 31 of these cell lines was assessed by microarray analysis.
2015-05-13 | E-MTAB-2971 | biostudies-arrayexpress
Project description:This study tests the feasibility and reproducibility of patient-specific motion models. These will be used for quantification of safe margin reduction. Patient-specific motion models will be built by post-processing 4D MRI data with non-rigid registration. By comparing these models between visits, model reproducibility will be assessed, and the methodology refined.
| 2026927 | ecrin-mdr-crc
Project description:In this study we want present a bank of metastatic colorectal cancer (mCRC) Patient Derived Organoids (PDOs) obtained from Patient Derived Xenografts (PDXs). These models are annotated with different omics to advance our understanding of CRC. We wanted to create a resource for the scientific community to assess the predictive reliability of these preclinical models. We performed comparative analyses between PDOs and matched PDXs to assess the similarities of these two platforms regarding molecular profiles and transcriptional classification. Moreover, we analyzed how these models respond to Cetuximab, a chimeric monoclonal antibody, normally given to patients after chemotherapy, that inhibits EGFR. After having assessed models’ reliability with Cetuximab, we aimed at identifying potential synergistic drugs to individuate new possible therapeutic prospects.
2023-03-01 | GSE204805 | GEO
Project description:This West Coast Metabolomics Center pilot and feasibility project was granted to Johanna Lampe (Fred Hutchinson Cancer Research Center at Univ. of Washington, Seattle). In the current investigation, unbiased profiling of the metabolome and lipidome of adipose tissue samples (visceral(VAT) and subcutaenous (SAT)) and serum of 50 CRC patients, including stages I-IV, from the Fred Hutchinson Cancer Center (Seattle,WA) and the German Cancer Research Center (Heidelberg, Germany) was conducted. The lipidome and metabolome of adipose tissue (VAT/SAT) and serum were analyzed using established UPLC-QTOFMS analysis and GC-TOFMS analyses, respectively. The primary objectives of this project were to 1) compare the metabolome and lipidome of matched VAT and SAT adipose tissue of n=50 Colorectal Cancer Cell (CRC) patients, 2) characterize the associations between the lipidome and metabolome in adipose tissue (VAT/SAT) and serum of n=50 CRC patients and 3) test the associations between the lipidome/metabolome of VAT and serum with the tumor stage of CRC patients.
2014-06-11 | ST000065 | MetabolomicsWorkbench